Literature DB >> 324929

Restoration by levamisole of histamine-inhibited E rosette formation of T lymphocytes of patients with allergies.

W De Cock, J De Crée, H Verhaegen.   

Abstract

Histamine significantly inhibited the E rosette formation of T lymphocytes of patients with allergies in vitro, but had no effect on the E rosette formation of T lymphocytes of healthy subjects. This inhibitory effect was obtained by concentrations of 3.10(-4) down to 3.10(-7) M histamine and depended on the time of incubation. Levamisole an antianergic chemotherapeutic agent, could restore the histamine-inhibited E rosette formation. It is postulated that patients with allergies possess a subpopulation of T lymphocytes bearing histamine receptors and that the inhibitory effect of histamine on E rosette formation is medicated by intracellular cAMP.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324929     DOI: 10.1159/000231822

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  4 in total

1.  Defective neutrophil chemotaxis and raised serum ige levels in a child with recurrent bacterial infections and eczema. Influence of levamisole.

Authors:  J De Cree; L Emmery; J Timmermans; R Eeckels; W De Cock; H Verhaegen
Journal:  Arch Dis Child       Date:  1978-02       Impact factor: 3.791

2.  Effect of histamine on the mitogenic response of human lymphocytes and its modification by cimetidine and levamisole.

Authors:  K Meretey; G Room; R N Maini
Journal:  Agents Actions       Date:  1981-04

3.  Suppressor effects of histamine on SK/SD delayed hypersensitivity reactions in man and on E-rosette-forming cells.

Authors:  U Ambanelli; G F Ferraccioli; P Mangenelli; G L Vanona
Journal:  Agents Actions       Date:  1979-12

4.  A child with atopic features, raised serum IgE, and recurrent infection treated with levamisole.

Authors:  L Businco; F Laurenti; P Rossi; E Galli; F Aiuti
Journal:  Arch Dis Child       Date:  1981-01       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.